Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — Aptorum Group — HCW Conference September 2025
16 slides from Niki BioSolutions's conference presentation, Sep 10, 2025
Slide 1: Aptorum Group & DiamiR Biosciences Merger Overview & Strategic Rationale
Alidad Mireskandari, Ph.D., MBA CEO, DiamiR Biosciences HCW Conference September 2025 Aptorum Group & DiamiR Biosciences Merger Overview & Strategic Rationale
Slide 2: Forward-Looking Statements Legal Disclaimer
Forward - Looking Statements Legal Disclaimer This presentation contains summary information about Aptorum Group Limited and DiamiR Biosciences Corp . (collectively, the “Companies”) as of the date hereof . The information in this presentation is of general background and contains an overview and su
Slide 3: Company Profiles
Company Profiles Aptorum Group Limited Focus : Clinical - stage biopharmaceutical company Specialization : Oncology (including orphan indications) and infectious diseases Listing : NASDAQ: APM Status : Dedicated to addressing unmet medical needs through drug discovery and development DiamiR Bioscien
Slide 4: Transaction Snapshot
Transaction Snapshot Share Exchange DiamiR shareholders 70%, Aptorum 30% Shareholder approval; SEC & Nasdaq review Conditions 1. Potential for DiamiR’s product candidates in brain health, cancer, and inflammatory diseases to create long - term value for the combined Company’s stockholders 2. Potenti
Slide 5: Expected Transaction Timelines
Expected Transaction Timelines Regulatory and Shareholder Approvals 4Q 2025 Pending stockholder approvals from both companies and completion of customary closing conditions Integration and Growth 2026 and Beyond Full operational integration and expansion of combined neurodiagnostic and therapeutics
Slide 6: Strategic Rationale
Strategic Rationale Accelerate R&D Invest in high value evidence generation studies. Enables development of Clinical and Pharma Services solutions specifically targeting aging - related and neurodegenerative diseases Portfolio Diversification Transforms APM from clinical - stage biopharma to diversi
Slide 7: Research Integration underway: Focus on Glioblastoma
Research Integration underway FOCUS ON GLIOBLASTOMA IP License Agreement Non - exclusive license of DiamiR's patents, trademarks, technology, and proprietary information Diagnostic Test Development DiamiR provide services to develop glioblastoma diagnostic test until merger close or Dec 31 , 2025 Le
Slide 8: DiamiR's Technology and Innovation Platform
DiamiR’s Technology and Innovation Platform Operating Clinical Laboratory CLIA Certified, CAP Licensed, NY state Approved Laboratory can handle R&D and clinical testing needs of combined companies Early Detection Solutions Pre - symptomatic testing enables identification of neurodegenerative disease
Slide 9: microRNA: Dynamic epigenetic biomarkers detectable in blood plasma
microRNA | Dynamic epigenetic biomarkers detectable in blood plasma miRNAs are short , non - coding, regulatory molecules whose expression levels change in disease miRNAs are master regulators of protein synthesis and cellular processes such as growth, inflammation, survival, and death miRNAs cross
Slide 10: Brain-enriched miRNAs are ideal diagnostic targets
• Simple blood draw • Plasma testing Brain - enriched miRNAs are ideal diagnostic targets Can Support clinical studies • Right patient for right study • Therapy target selection • Companion diagnostic Result in clinically actionable reports • Pre - symptomatic / early symptomatic (MCI) Risk Score •
Slide 11: CogniMIR: Overview of our proprietary risk-assessment test for AD
CogniMIR® | Overview of our proprietary, novel, risk - assessment test for AD * Diagnostics 2023, 13,2170. https://doi.org/10.3390/ FDA has not approved CogniMIR® for commercialization as of Sep 2025 Plasma Shipped to our CLIA Lab microRNA Risk Profiling Other Risk Factors Analyzed ML/Algorithm Anal
Slide 12: Market Opportunity for Alzheimer's Disease
Market Opportunity for Alzheimer's Disease Global AD diagnostics market size estimated at $9.94 Billion in 2025 Market us projected to reach around USD $25.53 billion by 2034, growing at a CAGR of 11.05% from 2025 to 2034 Population Impact 7.2M in 2025: Growing to 12.7M by 2050 Total lifetime cost o
Slide 13: DiamiR Partnerships | Collaborators and key stakeholders
DiamiR Partnerships | Collaborators and key stakeholders
Slide 14: Key Drivers of Growth in Neurodegenerative Diseases
Key Drivers of Growth in Neurodegenerative Diseases Demographic Trends Longer lifespans = higher incidence of chronic neurological conditions Aging global population increasing demand for early detection solutions Adaptation of Biomarkers FDA and Industry have adopted biomarkers as surrogates for tr
Slide 15: Summary | Advantages of Aptorum and DiamiR Merger
Summary | Advantages of Aptorum and DiamiR Merger Strengthens pipeline with diagnostics portfolio • Combines Aptorum's SACT - 1 therapeutic program (neuroblastoma treatment) with DiamiR's biomarker technology • CogniMIR ® , risk assessment test for mild cognitive impairment and Alzheimer’s analytica
Slide 16: Thank You Q&A
Thank You Q&A